SL
RPRX icon

Salomon & Ludwin’s Royalty Pharma RPRX Stock Holding History

Salomon & Ludwin’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.36K Hold
131
– – ﹤0.01% 1694
2025
Q4 		$5.19K Sell
131
-152
-54% -$5.8K ﹤0.01% 1764
2025
Q3 		$10.2K Buy
+283
New +$10.2K ﹤0.01% 1291

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Salomon & Ludwin's RPRX Position: Q1 2026 in Review

Salomon & Ludwin held its Royalty Pharma (RPRX) position steady in Q1 2026 at 131 shares worth $6.36K. The position accounts for ﹤0.01% of the portfolio, ranked #1694.

Salomon & Ludwin first reported a position in RPRX in Q3 2025 and has held it in 3 quarters since. The position peaked at $10.2K in Q3 2025. 587 funds tracked by Wall St. Rank hold RPRX as of Q1 2026.

  • Salomon & Ludwin held 131 shares of Royalty Pharma worth $6.36K as of Q1 2026.
  • Salomon & Ludwin left its Royalty Pharma share count unchanged in Q1 2026.
  • Royalty Pharma made up ﹤0.01% of Salomon & Ludwin's portfolio in Q1 2026, its #1694 holding.
  • Salomon & Ludwin first reported a position in Royalty Pharma in Q3 2025 and has held it in 3 quarters since.
  • Salomon & Ludwin's Royalty Pharma position peaked at $10.2K in Q3 2025.
  • 587 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2026.

Based on Salomon & Ludwin's 13F filing for Q1 2026, filed 11 May 2026.